Stanford inventors have identified a treatment regimen that allows expansion of cardiomyocytes (CMs) derived from human induced pluripotent stem cells in vitro.
Adeno-associated virus (AAV) vectored products are currently leading candidates for gene therapy applications with multiple approved products and many more in clinical trials.
Stanford inventors have developed a method to create spatially micropatterned vascularized structures that enable in vitro representation of human and animal biology in models such as cells, tissues, organs, and organoids.
The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.
Antimicrobial peptoids are promising leads for novel antibiotics; however, their activity is often compromised under physiological conditions. Inventors at Stanford enhanced the efficacy of antimicrobial peptoids by using thiourea and thiourea derivatives.
Researchers at Stanford have developed a gene expression-based method for determining a virally infected patient's risk of developing severe symptoms, irrespective of the virus.
Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Researchers in the Lee lab have discovered a totally novel approach to restore the impairment of empathy associated with many neurological disorders and mental illnesses.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Stanford researchers in the Swartz lab have developed a method for improving the productivity of biosynthetic processes via enzymatic detoxification of aberrant forms of NAD(P)H.